InvestSMART

AFT Pharmaceuticals Limited (ASX:AFP)

ALERT: Price-sensitive ASX Announcement for AFP
Current share price for AFP : $3.070 0.36 (13.28%)+
Announcement
Release
20 Nov 2025 7:31AM
Price at Release
$2.710
Full Release
download
Summary
AFT Pharmaceuticals Limited has reported significant growth across various markets, particularly in Australia and Asia. The company's interim presentation for FY26 highlights a strong increase in revenue driven by successful product launches and expansion efforts, especially in international markets where their revenues doubled. The company is on track to deliver a notable operating profit within the target range of $20 million to $24 million for FY26 and is working towards an ambitious revenue goal of $300 million by FY27. Continued investment in R&D and strategic market diversification are central to AFT's sustained growth strategy.
Key Points
  • AFT Pharmaceuticals experienced a substantial revenue growth of 31% in Australia, reaching $66.5 million.
  • The company's New Zealand revenues increased by 8%, with a focus on allergy, dermatology, and eyecare.
  • AFT's international revenues doubled to $11 million due to normal buying patterns and new product launches.
  • AFT Pharmaceuticals aims to achieve $300 million in annual revenue by FY27.
  • Significant R&D investments are underway to sustain long-term growth and geographical diversification.
  • The company plans to continue expanding its product portfolio, including Maxigesic, across various global markets.
  • AFT has a strategic focus on enhancing its presence in the Asian market, with a 69% revenue increase.
  • The company anticipates a strong second half of FY26, with expected greater sales and earnings.
  • AFT's research and development expenses are supported by positive cashflows.
  • The company has a robust inventory and is well-positioned for future growth investments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.